CPRX241220P12500
- 0.10
- 0.000.00%
Catalyst Pharmaceuticals Newsroom
Stephens Initiates Catalyst Pharmaceuticals(CPRX.US) With Buy Rating, Announces Target Price $35
Catalyst Pharmaceuticals Analyst Ratings
Stephens & Co. Initiates Coverage On Catalyst Pharmaceuticals With Overweight Rating, Announces Price Target of $35
Truist Financial Maintains Catalyst Pharmaceuticals(CPRX.US) With Buy Rating, Announces Target Price $36
BofA Securities Maintains Catalyst Pharmaceuticals(CPRX.US) With Buy Rating
Oppenheimer Maintains Catalyst Pharmaceuticals(CPRX.US) With Buy Rating, Maintains Target Price $29
Catalyst Pharmaceuticals Analyst Ratings
H.C. Wainwright Maintains Catalyst Pharmaceuticals(CPRX.US) With Buy Rating, Maintains Target Price $30
Truist Financial Maintains Catalyst Pharmaceuticals(CPRX.US) With Buy Rating
Citi Maintains Catalyst Pharmaceuticals(CPRX.US) With Buy Rating, Maintains Target Price $31
BofA Securities Maintains Catalyst Pharmaceuticals(CPRX.US) With Buy Rating, Announces Target Price $27
Catalyst Pharmaceuticals Analyst Ratings
Citigroup Maintains Buy on Catalyst Pharmaceuticals, Raises Price Target to $31
Catalyst Pharmaceuticals Analyst Ratings
Truist Adjusts Price Target on Catalyst Pharmaceuticals to $30 From $25, Maintains Buy Rating
Catalyst Pharmaceuticals Analyst Ratings
Catalyst Pharmaceuticals Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Catalyst Pharmaceuticals, Maintains $26 Price Target
HC Wainwright & Co. : The Catalyst Pharmaceuticals (CPRX.US) rating was maintained, adjusted from buy to buy rating, and the target price was adjusted from $24.00 to $26.00.
Catalyst Pharmaceuticals Analyst Ratings